C. Diff

There are two big news from the staple of Merck & Co., Inc. (NYSE: MRK) during the weekend. While the first related to KEYNOTE-045 meeting primary endpoint, the second is in respect of FDA approval for ZINPLAVA to reduce recurrence of clostridium difficile (C. Diff.) infection in adults....